
- Frederic Fasano named President and COO
- Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors
MONTREAL , Jan. 18, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th , to augment its senior leadership team and support expansion of Valeo’s commercial activities. Mr. Fasano has also been elected to the Company’s Board of Directors effective as of today.
“It gives me true pleasure to welcome Frederic to the Valeo executive team in this important new role. He possesses extensive International pharmaceutical experience and his management skills are well suited to helping us build a leading innovative pharmaceutical company with a deep commitment to our selected therapeutic areas of focus”, said Steve Saviuk, CEO. “This increase in management depth, coupled with our solid foundation of products and people, positions us well for the dynamic growth we foresee in the coming years.”
Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/753244-valeo-pharma-announces-major-addition-to-its-senior-management-team/messages/2298542#message
Tags: BioSyent Inc., CSE, HLS Therapeutics, investment, Knight Therapeutics, Medexus Pharmaceuticals, pharma, pharma stocks, Redesca, small cap, small cap pharma, stocks